Still a Lot of Potential in Dendreon and the Cancer Immunotherapy Market

Dendreon (DNDN) released an update on Thursday that outlined the path that the company is taking to advance its prostate cancer treatment Provenge to market.

In a mid-day PR, the company announced that they will file an NDA with the FDA in November and that the FDA would then be expected to act on the application by mid 2010. It is expected that the FDA will rule to approve Provenge, based on previous comments by the regulatory agency after mid term results were released last year. Keep in mind, however, that nothing is a sure thing both with regard to the stock market or the FDA. While indications point to an FDA approval, it is also good to realistically temper the enthusiasm by remembering that members of the FDA are humans - government officials, at that - and are just as likely to change their minds or ask for more information as anyone else out there.